細胞治療市場：足場別、用途別-2024-2030年の世界予測

細胞治療市場規模は2023年に110億7,000万米ドルと推計され、2024年には124億9,000万米ドルに達し、CAGR 13.37％で2030年には266億5,000万米ドルに達すると予測されています。

細胞治療は、組織や臓器の修復や再生を目的として細胞成分を利用する再生医療の一分野を表しています。これらの成分には、タンパク質、ペプチド、成長因子、細胞外マトリックス（ECM）成分、合成生理活性化合物など様々な生体分子が含まれるが、生きた細胞は含まれないです。この治療法は、このような細胞状物質が持つ潜在的な指導力を利用して、身体に内在する修復機構を刺激したり、組織再生のための足場を提供したりするものです。KEYWORD市場の成長は、慢性疾患の有病率の増加、治療技術の進歩、再生医療研究への投資の増加といった要因の影響を受けています。さらに、再生医療を支援する政府の積極的な取り組みも、細胞治療の提供を加速させています。しかし、治療開発の高コスト、厳しい規制要件、製造プロセスの複雑さが細胞治療の開発に影響を与えています。細胞治療市場の潜在的なビジネスチャンスとしては、生体適合性と生物活性を高めたバイオマテリアルの開拓、高度な製造技術のためのテクノロジー企業との提携、新興国の未開拓市場の開拓などが挙げられます。

地域別インサイト

米国を中心とする南北アメリカでは、創傷治癒、整形外科治療、最近では美容整形など、複数の臨床用途で細胞治療が広く採用されています。南北アメリカにおけるアセラー治療の生産は高度に洗練されており、厳格なFDA規制が最高の品質と安全基準を保証しています。APAC地域では、日本、韓国、中国、インドなどが細胞治療の重要な市場として台頭してきています。これらの国々では、糖尿病人口の増加により、慢性創傷や糖尿病性潰瘍の管理におけるこれらの治療法の使用が増加しています。さらに、経済成長とヘルスケア投資により、APACは急成長するメディカルツーリズムのハブとなり、細胞治療薬のような高度な治療法の使用に直接影響を与えています。中国と韓国は特に生産能力の拡大に投資しており、日本は再生医療における技術革新で知られています。欧州は、創傷治療、組織再生、外科的用途に使用される先進的な製品で、細胞治療市場が確立されています。この分野には多くの大手企業が進出しており、技術革新を牽引しています。中東とアフリカの一部でも細胞性製品の可能性が認識されつつあるが、広大な地域内で経済制度やヘルスケア制度が異なるため、その採用にはばらつきがあります。欧州諸国には、EMAガイドラインに準拠した強固な生産枠組みがあり、高品質の生産が保証されています。ドイツ、英国、フランスなどのバイオテクノロジー拠点は、強力な生産能力を有しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、細胞治療市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、ビジネス戦略と製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront（F）、Pathfinder（P）、Niche（N）、Vital（V）に分類されます。

市場シェア分析

市場シェア分析は、細胞治療市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、細胞治療市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患や加齢に伴う疾患の増加
    • 再生医療と幹細胞調査を推進する政府の取り組み
    • 無細胞およびスマートバイオマテリアルの利用可能性の向上
  • 抑制要因
    • 熟練した調査人材の不足と限られた償還オプション
  • 機会
    • 世界中で細胞治療の進歩と研究開発
    • 病院や医療機関が実施する細胞治療プロジェクトの増加
  • 課題
    • 再生医療と無細胞療法に関する複雑な規制
• 市場セグメンテーション分析
  • 足場：細胞外マトリックスのサポートの優先細胞治療
  • 用途：腫瘍学の腫瘍部位を標的とした細胞治療の開発
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 細胞治療市場Scaffold別

• 細胞を含んだハイドロゲル
• 細胞外マトリックス（ECM）
• 熱溶解積層法（FDM）

第7章 細胞治療市場：用途別

• 心臓病学
• 消化器内科
• 肝臓病学
• 神経学
• 腫瘍学

第8章 南北アメリカの細胞治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の細胞治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの細胞治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ヒューマサイト、血管外傷患者の治療におけるヒト無細胞血管（HAV）の第2/3相試験で良好なトップライン結果を発表
  • FDA、1型糖尿病の細胞療法「ランティドラ」を承認
  • ヒューマサイト社、ウクライナの最前線病院に血管外傷の治療用にヒト無細胞血管（HAV）を提供
• 戦略分析と提言

第12章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. ACELLULAR THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. ACELLULAR THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ACELLULAR THERAPY MARKET DYNAMICS
• FIGURE 7. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 12. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 14. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 20. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ACELLULAR THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CELL LADEN HYDROGEL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CELL LADEN HYDROGEL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY EXTRACELLULAR MATRIX (ECM), BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY EXTRACELLULAR MATRIX (ECM), BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY FUSED DEPOSITION MODELING (FDM), BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY FUSED DEPOSITION MODELING (FDM), BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY HEPATOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY HEPATOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 28. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 29. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 30. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 31. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 32. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 33. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 34. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 35. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 36. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 37. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 38. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 39. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 40. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 41. CANADA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 42. CANADA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 43. CANADA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 44. CANADA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 45. MEXICO ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 46. MEXICO ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 47. MEXICO ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 48. MEXICO ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 49. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 50. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 51. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 52. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 53. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 54. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 56. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 58. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 60. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 61. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 62. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 63. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 64. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 65. CHINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 66. CHINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 67. CHINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 68. CHINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 69. INDIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 70. INDIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 71. INDIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 72. INDIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 73. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 74. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 75. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 76. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 77. JAPAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 78. JAPAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 79. JAPAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 80. JAPAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 81. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 82. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 83. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 84. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 85. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 86. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 87. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 88. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 89. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 90. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 91. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 92. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 94. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 95. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 96. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 97. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 98. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 99. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 100. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 101. THAILAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 102. THAILAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 103. THAILAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 104. THAILAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 105. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 106. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 107. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 108. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 115. DENMARK ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 116. DENMARK ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 117. DENMARK ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 118. DENMARK ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 119. EGYPT ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 120. EGYPT ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 121. EGYPT ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 122. EGYPT ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 123. FINLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 124. FINLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 125. FINLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 126. FINLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 127. FRANCE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 128. FRANCE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 129. FRANCE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 130. FRANCE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 131. GERMANY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 132. GERMANY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 133. GERMANY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. GERMANY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 136. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 137. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 138. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 139. ITALY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 140. ITALY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 141. ITALY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 142. ITALY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 143. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 144. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 145. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 146. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 147. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 148. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 149. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 150. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 151. NORWAY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 152. NORWAY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 153. NORWAY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 154. NORWAY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 155. POLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 156. POLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 157. POLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 158. POLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 159. QATAR ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 160. QATAR ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 161. QATAR ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 162. QATAR ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 163. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 164. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 165. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 166. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 168. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 169. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 170. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 172. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 174. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 175. SPAIN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 176. SPAIN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 177. SPAIN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 178. SPAIN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 179. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 180. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 181. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 182. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 183. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 184. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 185. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 186. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 187. TURKEY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 188. TURKEY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 189. TURKEY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 190. TURKEY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 192. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 194. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
• TABLE 196. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
• TABLE 197. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 198. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 199. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 200. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

[195 Pages Report] The Acellular Therapy Market size was estimated at USD 11.07 billion in 2023 and expected to reach USD 12.49 billion in 2024, at a CAGR 13.37% to reach USD 26.65 billion by 2030.

Acellular therapy represents a branch of regenerative medicine that utilizes acellular components with the goal of repairing or regenerating tissues and organs. These components can include various biomolecules such as proteins, peptides, growth factors, extracellular matrix (ECM) components, and synthetic bioactive compounds but lack any living cells. This form of therapy harnesses the instructive potential of these acellular materials to stimulate the body's intrinsic repair mechanisms or to provide a scaffold for tissue regeneration. The growth of the acellular therapy market is influenced by factors such as the increasing prevalence of chronic diseases, advancements in treatment technology, and growing investments in regenerative medicine research. Further, favorable government initiatives to support regenerative medicine have also accelerated the provision of acellular therapy. However, the high cost of therapy development, stringent regulatory requirements, and the complexity of the manufacturing process impact the acellular therapy development. Potential opportunities within the acellular therapy market include the development of biomaterials with enhanced biocompatibility and bioactivity, collaboration with technology companies for advanced manufacturing techniques, and exploring untapped markets in developing countries.

Regional Insights

The Americas, particularly the United States, have witnessed widespread adoption of acellular therapy across multiple clinical applications, including wound healing, orthopedic treatments, and, increasingly, cosmetic procedures. The production of acellular therapies in the Americas is highly sophisticated, with stringent FDA regulations ensuring the highest quality and safety standards. In the APAC region, countries such as Japan, South Korea, China, and India are emerging as significant markets for acellular therapy. These countries are seeing increasing use of these therapies in managing chronic wounds and diabetic ulcers due to a growing diabetic population. Further, growing economies and healthcare investments have seen the APAC become a burgeoning medical tourism hub, directly impacting the use of advanced therapies such as acellular therapeutics. China and South Korea are particularly invested in scaling up production capacity, and Japan is known for its innovation in regenerative medicine. Europe has a well-established acellular therapy market, with advanced products used in wound care, tissue regeneration, and surgical applications. The presence of a number of leading companies here drives innovation in the sector. The Middle East and parts of Africa are also recognizing the potential for acellular products; however, their adoption is varied due to differing economic and healthcare systems within the vast region. European countries have robust production frameworks governed by EMA guidelines, which ensure high-quality production. Biotechnology hubs in countries including Germany, the UK, and France have strong production capabilities.

Market Insights

• Market Dynamics

The market dynamics represent an ever-changing landscape of the Acellular Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Growing prevalence of chronic diseases and age-related conditions
  • Government initiatives to propel regenerative medicine and stem cell research
  • Increased availability of acellular and smart biomaterials

• Market Restraints
  • Lack of skilled research personnel and limited reimbursement options

• Market Opportunities
  • Advancements and R&D in acellular therapy worldwide
  • Rising number of acellular therapy projects undertaken by hospitals and medical entities

• Market Challenges
  • Complex regulations pertaining to regenerative medicine and acellular therapies
• Market Segmentation Analysis
  • Scaffold: Preference for extracellular matrix to support acellular therapy
  • Application: Development of acellular therapy designed to target oncology tumor sites

• Market Disruption Analysis
• Porter's Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Acellular Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Acellular Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. unveiled promising results from its pivotal V005 Phase 2/3 study concerning the application of the Human Acellular Vessel (HAV) for emergency vascular trauma repair. This single-arm clinical trial demonstrated that HAV displayed a superior performance, with higher patency rates and notably fewer occurrences of amputation and infection when juxtaposed with historical data on synthetic vascular grafts. [Published On: 2023-09-12]

FDA Approves Lantidra, a Cellular Therapy for Type 1 Diabetes

The U.S. Food and Drug Administration (FDA) has greenlit Lantidra (donislecel-jujn), a pioneering cellular therapy treatment for adults with type 1 diabetes who consistently struggle to reach their target HbA1c levels due to recurrent severe hypoglycemia, despite undergoing rigorous diabetes management and education. Engineered as the first allogeneic pancreatic islet cell therapy sanctioned by the FDA, Lantidra facilitates insulin regulation through the delivery of allogeneic islet beta cells. [Published On: 2023-06-29]

Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries

Humacyte, Inc. a pioneering clinical-stage biotech firm specializing in the development of universally implantable bioengineered human tissues, has initiated a humanitarian project to distribute its revolutionary Human Acellular Vessels (HAVs) to several Ukrainian hospitals for critical vascular repair treatment in both civilians and military personnel suffering from vascular injuries. The inaugural batch of HAVs, designed as engineered, off-the-shelf vessels for a variety of vascular treatments, has embarked for Ukraine, targeting six medical facilities across cities including Kyiv and Kharkiv. [Published On: 2022-05-09]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Acellular Therapy Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Acellular Therapy Market, highlighting leading vendors and their innovative profiles. These include Allergan Inc. by Abbvie Inc., AlloSource, Aziyo Biologics, Baxter International, Becton, Dickinson and Company, BioHorizons, Inc., EnColl Corporation, Engitix Ltd, Fidia Farmaceutici S.p.A, GSK PLC, Humacyte, Inc., In2Bones Global by CONMED Corporation, Integra LifeSciences Corporation, LifeNet Health, MiMedx Group, Organicell Regenerative Medicine, Inc., Organogenesis Holdings Inc., Reprise Biomedical, Inc., Sanofi S.A., Smith & Nephew PLC, Stryker Corporation, Tissue Regenix, Vascudyne, Inc., and Zimmer Biomet.

Market Segmentation & Coverage

This research report categorizes the Acellular Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Scaffold
  • Cell Laden Hydrogel
  • Extracellular Matrix (ECM)
  • Fused Deposition Modeling (FDM)

• Application
  • Cardiology
  • Gastroenterology
  • Hepatology
  • Neurology
  • Oncology

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of chronic diseases and age-related conditions
    • 5.1.1.2. Government initiatives to propel regenerative medicine and stem cell research
    • 5.1.1.3. Increased availability of acellular and smart biomaterials
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of skilled research personnel and limited reimbursement options
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements and R&D in acellular therapy worldwide
    • 5.1.3.2. Rising number of acellular therapy projects undertaken by hospitals and medical entities
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulations pertaining to regenerative medicine and acellular therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Scaffold: Preference for extracellular matrix to support acellular therapy
  • 5.2.2. Application: Development of acellular therapy designed to target oncology tumor sites
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Acellular Therapy Market, by Scaffold

• 6.1. Introduction
• 6.2. Cell Laden Hydrogel
• 6.3. Extracellular Matrix (ECM)
• 6.4. Fused Deposition Modeling (FDM)

7. Acellular Therapy Market, by Application

• 7.1. Introduction
• 7.2. Cardiology
• 7.3. Gastroenterology
• 7.4. Hepatology
• 7.5. Neurology
• 7.6. Oncology

8. Americas Acellular Therapy Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Acellular Therapy Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Acellular Therapy Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma
  • 11.3.2. FDA Approves Lantidra, a Cellular Therapy for Type 1 Diabetes
  • 11.3.3. Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries
• 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

• 12.1. Key Company Profiles
• 12.2. Key Product Portfolio